Table 4.
Frequency of polymorphisms in the FOXP3 gene promoter region according to the histopathological characteristics of patients with chronic hepatitis B and C virus infections.
| Infection and genetic profile | Degree of inflammatory activity | Degree of liver fibrosis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Absent to mild | Moderate to severe | p1 | Absent to mild | With few septa | Advanced to cirrhosis | p2 | p3 | p4 | |
| n (%) | n (%) | n (%) | n (%) | n (%) | |||||
| −2383C>T | |||||||||
| CHC | |||||||||
| CC | 35 (87.50) | 26 (92.86) | 0.6147 | 24 (88.89) | 16 (94.12) | 32 (91.43) | 0.6808 | 0.5221 | 1.0000 |
| CT | 4 (10.00) | 2 (07.14) | 2 (07.41) | 1 (05.88) | 3 (08.57) | ||||
| TT | 1 (02.50) | 0 | 1 (03.71) | 0 | 0 | ||||
| CHB-I | |||||||||
| CC | 6 (66.67) | – | – | 6 (66.67) | – | – | – | – | – |
| CT | 0 | – | 0 | – | – | ||||
| TT | 3 (33.33) | – | 3 (33.33) | – | – | ||||
| CHB-A | |||||||||
| CC | 13 (86.67) | 5 (100.00) | 0.7014 | 8 (88.89) | 8 (88.89) | 8 (100.00) | 0.3973 | 1.0000 | 1.0000 |
| CT | 1 (06.67) | 0 | 1 (11.11) | 0 | 0 | ||||
| TT | 1 (06.67) | 0 | 0 | 1 (11.11) | 0 | ||||
| −3279C>A | |||||||||
| CHC | |||||||||
| CC | 31 (77.50) | 20 (71.42) | 0.6840 | 22 (81.48) | 11 (64.70) | 27 (77.14) | 0.3043 | 0.7484 | 0.6046 |
| AC | 6 (15.00) | 4 (14.29) | 4 (14.81) | 3 (17.65) | 5 (14.29) | ||||
| AA | 3 (07.50) | 4 (14.29) | 1 (03.70) | 3 (17.65) | 3 (08.57) | ||||
| CHB-I | |||||||||
| CC | 7 (77.78) | – | – | 7 (77.78) | – | – | – | – | – |
| AC | 1 (11.11) | – | – | 1 (11.11) | – | – | |||
| AA | 2 (22.22) | – | – | 2 (22.22) | – | – | |||
| CHB-A | |||||||||
| CC | 10 (66.67) | 4 (80.00) | 0.3131 | 5 (50.00) | 7 (87.50) | 6 (66.67) | 0.0943 | 0.5462 | 0.1253 |
| AC | 1 (06.67) | 1 (20.00) | 1 (10.00) | 1 (12.50) | 0 | ||||
| AA | 4 (26.66) | 0 | 4 (40.00) | 0 | 3 (33.33) | ||||
| −924A>G | |||||||||
| CHC | |||||||||
| AA | 18 (45.00) | 13 (46.43) | 0.9920 | 9 (33.33) | 9 (52.94) | 19 (54.29) | 0.4320 | 0.2669 | 0.9562 |
| AG | 9 (22.50) | 6 (21.43) | 8 (29.63) | 3 (17.65) | 7 (20.00) | ||||
| GG | 13 (32.50) | 9 (32.14) | 10 (37.04) | 5 (29.41) | 9 (25.71) | ||||
| CHB-I | |||||||||
| AA | 3 (30.00) | – | – | 3 (30.00) | – | – | – | – | – |
| AG | 1 (10.00) | – | 1 (10.00) | – | – | ||||
| GG | 6 (60.00) | – | 6 (60.00) | – | – | ||||
| CHB-A | |||||||||
| AA | 4 (25.00) | 2 (40.00) | 0.8404 | 1 (10.00) | 5 (55.56) | 2 (20.00) | 0.1108 | 0.7890 | 0.3130 |
| AG | 4 (25.00) | 1 (20.00) | 3 (30.00) | 1 (11.11) | 2 (20.00) | ||||
| GG | 8 (50.00) | 2 (40.00) | 6 (60.00) | 3 (33.33) | 6 (60.00) | ||||
p1, Inflammation absent to mild vs. moderate to severe; p2, Fibrosis absent to mild vs. with few septa; p3, Fibrosis absent to mild vs. advanced to cirrhosis; p4, Fibrosis with few septa vs. advanced to cirrhosis.